financetom
Business
financetom
/
Business
/
BRIEF-Prysmian To Acquire Encore Wire For $290 Per Share In Cash
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Prysmian To Acquire Encore Wire For $290 Per Share In Cash
Apr 14, 2024 9:29 PM

April 15 (Reuters) - Prysmian - Prysmian Spa ( PRYMF ): To Acquire

Encore Wire For $290.00 Per Share In Cash:

* ITALY'S PRYSMIAN - TRANSACTION, ENCORE WIRE'S ( WIRE ) IMPLIED

ENTERPRISE VALUE IS APPROXIMATELY EUR 3.9 BILLION1

* AT TERMS OF TRANSACTION, ENCORE WIRE'S ( WIRE ) IMPLIED ENTERPRISE

VALUE

IS APPROXIMATELY EUR 3.9 BILLION

* PRYSMIAN EXPECTS TO GENERATE RUN-RATE PRE-TAX SYNERGIES OF

APPROXIMATELY EUR 140 MILLION WITHIN 4 YEARS FROM CLOSING

* TRANSACTION GROWS PRYSMIAN'S NORTH AMERICA EXPOSURE,

ENHANCING

GEOGRAPHICAL AND BUSINESS PORTFOLIO

* DEAL WILL GENERATE ABOUT EUR 140M IN RUN-RATE EBITDA

SYNERGIES

EXPECTED WITHIN 4 YEARS FROM CLOSING

* ITALY'S PRYSMIAN - EXPECTS TO GENERATE RUN-RATE PRE-TAX

SYNERGIES OF APPROXIMATELY EUR 140 MILLION WITHIN 4 YEARS FROM

CLOSING

* ITALY'S PRYSMIAN -TRANSACTION WILL BE FINANCED THROUGH MIX

OF

CASH ON PRYSMIAN'S BALANCE SHEET (€1.1 BILLION) AND NEWLY

COMMITTED DEBT FACILITIES (€3.4 BILLION).

* PRO-FORMA NET DEBT FOR COMBINED GROUP OF APPROXIMATELY EUR

5.1

BILLION, REPRESENTING A 2.4X 2023 ND/ADJUSTED. EBITDA RATIO

* PRYSMIAN TO ACQUIRE ENCORE WIRE FOR $290.00 PER SHARE IN

CASH

Source text for Eikon:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Groupe Dynamite Q3 Adjusted Profit, Revenue Advance
Groupe Dynamite Q3 Adjusted Profit, Revenue Advance
Dec 17, 2024
07:35 AM EST, 12/17/2024 (MT Newswires) -- Groupe Dynamite ( GRGDF ) on Tuesday reported higher third-quarter adjusted profit and revenue that beat estimates. The company, which operates two women's clothing brands, said adjusted diluted net earnings increased to $43.7 million, or $0.41 per share, from $35.7 million, or $0.33 per share, last year. The result beat the consensus analyst...
Marimaca Copper Secures Option to Buy Madrugador Project in Chile
Marimaca Copper Secures Option to Buy Madrugador Project in Chile
Dec 17, 2024
07:32 AM EST, 12/17/2024 (MT Newswires) -- Marimaca Copper ( MARIF ) said Tuesday that it signed a binding option agreement to acquire the Madrugador project in Chile. The company said Madrugador is located near the Pampa Medina project, and the acquisition consolidated its ownership of the southern extent of the Sierra de Medina property package. Under the terms, Marimaca...
Teva, Sanofi say drug to treat IBD met primary targets
Teva, Sanofi say drug to treat IBD met primary targets
Dec 17, 2024
JERUSALEM, Dec 17 (Reuters) - Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals. Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping it will become a blockbuster drug - or one...
IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial
IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial
Dec 17, 2024
07:30 AM EST, 12/17/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Tuesday an independent data monitoring committee has recommended a move-forward dose for a potential registration-enabling phase 2/3 trial to evaluate the company's darovasertib combined with Pfizer's ( PFE ) crizotinib in patients with a certain metastatic uveal melanoma. Chief Medical Officer Darrin Beaupre said the committee's recommendation...
Copyright 2023-2026 - www.financetom.com All Rights Reserved